Takahashi, Masato
Osako, Tomofumi
Yasojima, Hiroyuki
Inoue, Kenichi
Kawashima, Masahiro
Maeda, Hideki
Ichikawa, Akemi
Muramatsu, Yasuaki
Masuda, Norikazu
Clinical trials referenced in this document:
Documents that mention this clinical trial
Overall survival in Japanese patients with ER+/HER2− advanced breast cancer treated with first-line palbociclib plus letrozole
https://doi.org/10.1007/s12282-023-01511-z
Funding for this research was provided by:
Pfizer
Article History
Received: 2 August 2023
Accepted: 2 October 2023
First Online: 26 October 2023
Declarations
:
: MT reports honoraria from AstraZeneca, Daiichi-Sankyo, Eisai, Eli Lilly, MSD, and Pfizer. KI reports institutional support from MSD, Daiichi-Sankyo, Chugai, AstraZeneca, Sanofi, Astellas, Ono, Takeda, Eisai, Gilead, and Novartis. MK reports honoraria from Guardant Health, Chugai, Daiichi-Sankyo, Pfizer, and Eisai; and institutional support from Nippon Kayaku, Kyowa Kirin, Guardant Health, Shimadzu, GL Sciences; and clinical trial investigator support from JBCRG, Roche, Eli Lilly, MSD, and Chugai. AI and YM are employees of and stockholders in Pfizer Inc. NM reports honoraria from Chugai, Pfizer, AstraZeneca, Eli Lilly, and Daiichi -Sankyo; and institutional support from Chugai, Eli Lilly, AstraZeneca, Pfizer, Daiichi-Sankyo, MSD, Eisai, Novartis, Sanofi, KyowaKirin, and Nippon Kayaku. TO, HY and HM have no disclosures.